All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked: Do we need new endpoints to assess spleen response in MPN?
John Mascarenhas thinks yes, spleen-related endpoints used in clinical trials evaluating MPN-directed therapies should be reassessed. This interview highlights alternative MPN-related symptoms for consideration.
Do we need new endpoints to assess spleen response in MPN?
MANIFEST study: Should CPI-0610 be used as an add-on to ruxolitinib in patients with advanced MF?
The MPN Hub were pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US, during the 61st American Society of...
Trial update of the MANIFEST study of CPI-0610 in patients with myelofibrosis from EHA 2020
MANIFEST (NCT02158858) is a phase II clinical trial of CPI-0610, a small molecule inhibitor of bromodomain and extraterminal (BET) proteins, with and without...
Subscribe to get the best content related to MPN delivered to your inbox